Newsroom

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported estimated full-year consolidated financial results for 2025,1 as reviewed by the Audit Committee and the Board of Directors on March 25, 2026. The Board of Directors will approve the final accounts on A...

PARIS--(BUSINESS WIRE)--Regulatory News: GenSight Biologics (Euronext : SIGHT, ISIN: FR0013183985, éligible PEA-PME), société biopharmaceutique dédiée au développement et à la commercialisation de thérapies géniques innovantes pour les maladies neurodégénératives de la rétine et du système nerveux central, publie aujourd’hui ses résultats financiers consolidés estimés pour l’année 2025, tels qu'ils ont été examinés par le Comité d'Audit et par le Conseil d'Administration en date du 25 mars 2026...

TOKYO--(BUSINESS WIRE)--A fund which is provided discretionary investment management services by 3D Investment Partners Pte. Ltd. (together with such fund, “3D” or “we”) demanded, in December 2025, Toho Holdings Co., Ltd. (TOKYO: 8129, "Toho HD") file a lawsuit with respect to alleged breaches of the duty of care of the directors arising from past bid‑rigging misconduct involving current and former directors of Toho HD. In response, the Audit and Supervisory Committee of Toho HD decided not to...

WARSAW, Poland--(BUSINESS WIRE)--The Polish Investment and Trade Agency (PAIH) has named Ascend Elements’ Project Apex 2 its Manufacturing Investment of the Year, focused on the company’s development of the EU’s first fully integrated battery materials refining center that will turn spent lithium‑ion batteries into new, low‑carbon cathode materials using its Hydro‑to‑Cathode® technology. The Republic of Poland has granted Ascend Elements USD 320 million (approximately 1.22 billion PLN) to advan...

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – eligible for PEA PME), a next-generation biopharmaceutical company developing innovative therapies in sepsis and critical care based on an exclusive apoA-I technology platform, today announced a significant technological and industrial breakthrough combining high-performance apoA-I bioproduction with exclusive mastery of ultra-pure synthetic sphingomyelin, paving the way for a new clas...

TOULOUSE, France & FULLERTON, Calif.--(BUSINESS WIRE)--Regulatory News: ABIONYX Pharma, (FR0012616852 – ABNX – éligible PEA PME), société biopharmaceutique de nouvelle génération qui développe des thérapies innovantes dans le sepsis et les soins intensifs, fondées sur une plateforme technologique exclusive basée sur l’apoA- I, annonce aujourd’hui une avancée décisive combinant bioproduction haute performance de l’apolipoprotéine A-I (apoA-I) et maîtrise exclusive d’une sphingomyéline synthétiqu...

KYOTO, Japan--(BUSINESS WIRE)--Nidec Corporation (the “Company”), as part of its efforts to strengthen corporate governance based on the report of the Third-Party Committee published on March 3 as well as the Improvement Plan and the Status Report published by the Company on January 28, is revising the composition of its Board of Directors so that the Board can perform its functions effectively by including directors who possess diverse knowledge, experience, and expertise. In advance of the 53...

LOS ANGELES--(BUSINESS WIRE)--Unified Production Platform (UPP) today announced its official launch, led by founder Mujeebur Rahmansaher and partners Greg Smith and An De Vooght—three entertainment industry veterans who collectively built, scaled, and successfully exited one of the industry’s most prominent production companies. UPP is a SaaS-based, cloud-native, AI-powered production management platform that unifies casting, payroll, compliance, analytics, and workflow management into a single...

OSAKA, Japan--(BUSINESS WIRE)--NTT Solmare Corporation and Good Smile Company, Inc. have announced the joint production of a new visual novel game, "Obey Me! Sinner's Choice" ....

ARLINGTON, Virginia & MAILAND--(BUSINESS WIRE)--Venture Global und Edison gaben heute gemeinsam die Unterzeichnung einer Vereinbarung zur Beilegung des anhängigen Schiedsverfahrens zwischen den beiden Unternehmen bezüglich des Calcasieu-Pass-Projekts bekannt. Der Abschluss der Vereinbarung wird für Ende des zweiten Quartals 2026 erwartet; zu diesem Zeitpunkt wird das Schiedsverfahren beendet. Die Vereinbarung führt zu einer vollständigen Beilegung des Streitfalls. Im Rahmen der Einigung haben E...